HEPATOBILIARY CANCER | AUDITORIUM 1
See schedule

9 MAY 2017

HEPATOBILIARY CANCER | AUDITORIUM 1

Directors: Tânia Rodrigues | José António Pereira | Pedro Amado

 

HEPATOBILIARY SESSION

Colorectal cancer is one of the most common cancers in Western countries and the third cancer-related cause of death in the world. About 50% of patients with colorectal cancer will experience liver metastases during their lifetime, and about 25% of patients present with synchronous liver metastases at the same time as the diagnosis.

Over the last two decades, the approach to liver metastases of colorectal carcinoma has improved substantially, which has translated into a significant improvement in the survival of these patients. This improvement reflects the growing number of patients being treated within experienced multidisciplinary teams in centres of reference offering the required diagnostic and therapeutic resources.

Incidence of cholangiocarcinoma, a malignant tumor that grows with age, has also been increasing in the past two decades. Intrahepatic cholangiocarcinoma is the second most common primary liver tumor after hepatocellular carcinoma.

Surgery plays a central role in the treatment of liver metastases and intrahepatic cholangiocarcinoma insofar as it is the only therapy (in combination with others) with curative potential.